<DOC>
	<DOCNO>NCT02663193</DOCNO>
	<brief_summary>The purpose study characterize tolerability profile enzalutamide abiraterone acetate ( prednisone ) -with specific focus central nervous system ( CNS ) tolerability-and quality life ( QoL ) approximately 2 month participant start treatment one agents metastatic castration-resistant prostate cancer ( mCRPC ) .</brief_summary>
	<brief_title>Real-World Study Enzalutamide Abiraterone Acetate ( With Prednisone ) Tolerability</brief_title>
	<detailed_description>This multicenter ( one study site ) , open-label ( people know identity intervention ) , prospective , observational study characterize tolerability profile treatment quality life ( QoL ) participant receive enzalutamide abiraterone acetate ( prednisone ) clinical practice set . Approximately 100 male participant enrol study , 50 participant recruit treatment arm . Participants complete 2 schedule on-site visit ( Baseline Month 2 ) . Participants primarily observe tolerability profile enzalutamide abiraterone acetate ( prednisone ) safety observational period 2 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Male 18 year age old Have confirm metastatic adenocarcinoma prostate Are start treatment enzalutamide abiraterone acetate ( prednisone ) metastatic castrationresistant prostate cancer ( mCRPC ) full recommend dose per drug 's respective prescribing information ( PI ) Have Eastern Cooperative Oncology Group Performance Status score 0 1 Sign write informed consent Have preexist central nervous system ( CNS ) condition ( include , limited , history stroke dementia ) , participate physician 's judgment , would preclude participation study Have know mental illness include , limit , major depressive disorder , general anxiety disorder , bipolar disorder , participate physician 's opinion , could significantly confound patientreported outcome ( PRO ) assessment Have history ongoing seizure disorder Have severe hepatic impairment ( ChildPugh Class C ) Have active infection ( example , human immunodeficiency virus [ HIV ] , viral hepatitis ) medical condition would contraindicate use prednisone/prednisolone ( systemic glucocorticoid ) Have know alcohol substance abuse disorder Are routinely take medicationincluding , limited , overthecounter medication , supplement , medical marijuana prescription pain medicationthat know cause mental confusion sedation use medication Are routinely take systemic glucocorticoid ( example , prednisone , prednisolone , dexamethasone ) dosage high equivalent prednisone 10 milligram ( mg ) daily Are currently use previously use chemotherapy cancer include mCRPC Are concurrently use firstgeneration androgenreceptor blocker ( example , bicalutamide , flutamide , nilutamide ) mCRPC Have previously take enzalutamide abiraterone acetate prednisone Are capable complete test use computerized system complete participant survey</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Observational study</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>Abiraterone Acetate</keyword>
	<keyword>Prednisone</keyword>
	<keyword>Tolerability</keyword>
</DOC>